APAC’s fibromyalgia treatment market to advance until 2034

Meanwhile, the global market is expected to hit $2.9b within the forecast period.

The Asia Pacific (APAC) fibromyalgia treatment market is poised to witness notable growth until 2034, according to Transparency Market Research.

The report revealed that its expansion is driven by improving healthcare infrastructure in countries such as India and China.

Moreover, the region observed an increase in export volumes of generic drugs associated with fibromyalgia treatment.

“Collaborations between international pharmaceutical giants and local companies are facilitating the introduction of new therapies, contributing to the market's development in APAC,” the report said.

Meanwhile, the global fibromyalgia treatment market is expected to reach $2.9b by 2034 at an estimated compound annual growth rate (CAGR) of 3.8%.

Its projected growth is attributed to the rising awareness and diagnosis of the disorder, characterised by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive issues.

Moreover, the market is witnessing a trend towards innovation.

Such advancements include new therapeutic approaches like biologics, monoclonal antibodies, and other novel drug classes, as well as the integration of digital technologies, such as telemedicine and mobile health applications.